Javascript must be enabled to continue!
Selective blockade of AT 1 R and B 1 R modulates the expression of ACE2 ubiquitination partners
View through CrossRef
Angiotensin Converting Enzyme 2 (ACE2) is an important compensatory enzyme in the renin‐angiotensin system (RAS), converting Angiotensin (Ang)‐II to Ang‐(1‐7). We previously reported that Ang‐II mediates ACE2 internalization through its type 1 receptor (AT
1
R), followed by ubiquitination and degradation in lysosomes. We recently identified UBR1 and BRCC36, as potential ubiquitinase and deubiquitinase, respectively, modulating ACE2 expression in hypertensive conditions. Here, we aimed to evaluate the role of bradykinin B
1
R receptor in Ang‐II‐mediated ACE2 internalization and the enzyme’s ubiquitination partners in hypertension.
C57BI/6J mice (3‐month‐old, n=3/group) were divided into 3 groups: control (Ctrl), B
1
R antagonist SSR240612 (SSR), AT
1
R antagonist Losartan (Los). Mice were implanted with blood pressure (BP) probes (telemetry) and upon recovery, baseline BP was recorded for 24 hours. Mice were then implanted subcutaneously with an osmotic pump containing Ang‐II (490 ng/Kg/min/4 weeks) or saline. BP was recorded weekly, for 4 weeks. After 2weeks of Ang‐II infusion, the mice were implanted with an additional osmotic pump containing Losartan (30 mg/Kg/min) or SSR240612 (10 mg/Kg/min) for 2 weeks. Animals were sacrificed and the heart was isolated from all groups and protein expression for UBR1, BRCC36 and ACE2 was assessed using capillary western. Clinical relevance was further assessed in human heart left ventricle tissues of normal and hypertensive donors.
Ang‐II infusion induced a significant increase in mean BP in Ctrl group (159.2±1.5
vs.
100.6±0.5 mmHg; one‐way ANOVA, **P<0.001) after 4 weeks of infusion. This was significantly attenuated with blockade of B
1
R or AT
1
R (SSR: 98.8±0.6; Los: 99.6±0.8 mmHg; n=3: one‐way ANOVA, **P<0.001). Capillary western with mouse heart tissue confirmed that Ang‐II‐induced a significant 2‐fold increase (*P<0.05) in UBR1 expression and the SSR240612 treatment contributed to a significant 4‐fold increase (**P<0.001). However, losartan had no effect. BRCC36 expression in Ang‐II, losartan and SSR240612 treated group was significantly decreased by 2‐3‐fold (*P<0.05). However, Ang‐II induced decrease in ACE2 levels was significantly attenuated by losartan and SSR240612 (**P<0.001), indicating both B1R and AT1R receptors contribute to ACE2 internalization and degradation. In human’s, the UBR1 expression was 2 folds (*P<0.05) higher in hypertensive CA male and AA female and BRCC36 expression showed 2 folds decrease (*P<0.05) in CA hypertensive females. However, ACE2 expression showed 3 folds decrease in hypertensive CA males, indicating elevated levels of UBR1 mediated ACE2 ubiquitination and degradation in hypertensive conditions.
Our data show that Ang‐II‐mediated hypertension was attenuated with inhibition of both AT1R and B1R receptor, while B1R contributed to upregulation of UBR1 and both AT1R and B1R contributes to downregulation of BRCC36. Therefore, inhibition of both AT1R and B1R modulates the expression of ACE2 ubiquitination partners and also inhibits ACE2 internalization and degradation. Therefore, developing a treatments strategy and simultaneously targeting AT1R, B1R, UBR1 and BRCC36, involved in the regulation of ACE2 expression may be effective for the treatment of cardiovascular disorders.
Title: Selective blockade of AT
1
R and B
1
R modulates the expression of ACE2 ubiquitination partners
Description:
Angiotensin Converting Enzyme 2 (ACE2) is an important compensatory enzyme in the renin‐angiotensin system (RAS), converting Angiotensin (Ang)‐II to Ang‐(1‐7).
We previously reported that Ang‐II mediates ACE2 internalization through its type 1 receptor (AT
1
R), followed by ubiquitination and degradation in lysosomes.
We recently identified UBR1 and BRCC36, as potential ubiquitinase and deubiquitinase, respectively, modulating ACE2 expression in hypertensive conditions.
Here, we aimed to evaluate the role of bradykinin B
1
R receptor in Ang‐II‐mediated ACE2 internalization and the enzyme’s ubiquitination partners in hypertension.
C57BI/6J mice (3‐month‐old, n=3/group) were divided into 3 groups: control (Ctrl), B
1
R antagonist SSR240612 (SSR), AT
1
R antagonist Losartan (Los).
Mice were implanted with blood pressure (BP) probes (telemetry) and upon recovery, baseline BP was recorded for 24 hours.
Mice were then implanted subcutaneously with an osmotic pump containing Ang‐II (490 ng/Kg/min/4 weeks) or saline.
BP was recorded weekly, for 4 weeks.
After 2weeks of Ang‐II infusion, the mice were implanted with an additional osmotic pump containing Losartan (30 mg/Kg/min) or SSR240612 (10 mg/Kg/min) for 2 weeks.
Animals were sacrificed and the heart was isolated from all groups and protein expression for UBR1, BRCC36 and ACE2 was assessed using capillary western.
Clinical relevance was further assessed in human heart left ventricle tissues of normal and hypertensive donors.
Ang‐II infusion induced a significant increase in mean BP in Ctrl group (159.
2±1.
5
vs.
100.
6±0.
5 mmHg; one‐way ANOVA, **P<0.
001) after 4 weeks of infusion.
This was significantly attenuated with blockade of B
1
R or AT
1
R (SSR: 98.
8±0.
6; Los: 99.
6±0.
8 mmHg; n=3: one‐way ANOVA, **P<0.
001).
Capillary western with mouse heart tissue confirmed that Ang‐II‐induced a significant 2‐fold increase (*P<0.
05) in UBR1 expression and the SSR240612 treatment contributed to a significant 4‐fold increase (**P<0.
001).
However, losartan had no effect.
BRCC36 expression in Ang‐II, losartan and SSR240612 treated group was significantly decreased by 2‐3‐fold (*P<0.
05).
However, Ang‐II induced decrease in ACE2 levels was significantly attenuated by losartan and SSR240612 (**P<0.
001), indicating both B1R and AT1R receptors contribute to ACE2 internalization and degradation.
In human’s, the UBR1 expression was 2 folds (*P<0.
05) higher in hypertensive CA male and AA female and BRCC36 expression showed 2 folds decrease (*P<0.
05) in CA hypertensive females.
However, ACE2 expression showed 3 folds decrease in hypertensive CA males, indicating elevated levels of UBR1 mediated ACE2 ubiquitination and degradation in hypertensive conditions.
Our data show that Ang‐II‐mediated hypertension was attenuated with inhibition of both AT1R and B1R receptor, while B1R contributed to upregulation of UBR1 and both AT1R and B1R contributes to downregulation of BRCC36.
Therefore, inhibition of both AT1R and B1R modulates the expression of ACE2 ubiquitination partners and also inhibits ACE2 internalization and degradation.
Therefore, developing a treatments strategy and simultaneously targeting AT1R, B1R, UBR1 and BRCC36, involved in the regulation of ACE2 expression may be effective for the treatment of cardiovascular disorders.
Related Results
Viral stimulation modulates endotype-related ACE2 expression in eosinophilic chronic rhinosinusitis
Viral stimulation modulates endotype-related ACE2 expression in eosinophilic chronic rhinosinusitis
Background: Angiotensin-converting enzyme 2 (ACE2), a receptor targeted by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly expressed in the nasal mucosa...
Comprehensive Bioinformatics analysis of angiotensin-converting enzyme 2 (ACE2)
Comprehensive Bioinformatics analysis of angiotensin-converting enzyme 2 (ACE2)
Abstract
ACE2, a member of the angiotensin converting enzyme family, plays an irreplaceable role in the renin-angiotensin system. And the variations of ACE2 are regarded as...
GW24-e1111 The effects of ACE2 on RAS system by painting on epicadial in atrial rapid pacing canine
GW24-e1111 The effects of ACE2 on RAS system by painting on epicadial in atrial rapid pacing canine
Objectives
To study the effects of ACE2 on RAS system in rapid atrial pacing canine, and to investigate the possible mechanisms of ACE2 in improving atrial fibril...
Perindopril Reduce SARS-COV-2 Spike-ACE2 Binding, ACE2 Overexpression and Cytokine Storm in Adipocyte Cell Infected with SARS-COV-2
Perindopril Reduce SARS-COV-2 Spike-ACE2 Binding, ACE2 Overexpression and Cytokine Storm in Adipocyte Cell Infected with SARS-COV-2
Abstract
Funding Acknowledgements
Type of funding sources: Public Institution(s). Main funding source(s): Ristekdikti
...
Abstract P431: SARS-CoV-2-induced Inflammation In Human Endothelial Cells Involves ACE2
Abstract P431: SARS-CoV-2-induced Inflammation In Human Endothelial Cells Involves ACE2
COVID-19 is associated with hypertension, where endotheliitis and endothelial dysfunction are risk factors. Considering the relationship between the viral spike protein and ACE2, i...
ACE2 Ubiquitination is Differentially Regulated by Sex Hormones in Hypertension
ACE2 Ubiquitination is Differentially Regulated by Sex Hormones in Hypertension
Angiotensin Converting Enzyme 2 (ACE2) is a compensatory enzyme converting Angiotensin (Ang)‐II to Ang‐(1‐7). Previously, we reported that ACE2 is expressed on neurons in the brain...
Exploring the role of glycans in the interaction of SARS-CoV-2 RBD and human receptor ACE2
Exploring the role of glycans in the interaction of SARS-CoV-2 RBD and human receptor ACE2
Abstract
COVID-19 is a highly infectious respiratory disease caused by the novel coronavirus SARS-CoV-2. It has become a global pandemic and its frequent mutations ...
Abstract MP28: UBR1 And BRCC36 Regulate ACE2 Ubiquitination And Deubiquitination In Ang-II Induced Hypertension.
Abstract MP28: UBR1 And BRCC36 Regulate ACE2 Ubiquitination And Deubiquitination In Ang-II Induced Hypertension.
UBR1 and BRCC36 regulate ACE2 Ubiquitination and Deubiquitination in Ang-II induced Hypertension.
Navya Lakkappa
1
, Clara Berdasco
...

